Skip to main content

Remote Job Finders (RJF)

Zanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, which intends to leverage the foothold for more approvals in rare neurodegenerative diseases, including Angelman syndrome.
FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease
Scroll to top